# US 12,344,583 B2 · Solid psilocin salts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,344,583 B2
- Document ID: US12344583B2
- Status: Granted
- Kind: B2
- Application number: 18/888,371
- Filed: 2024-09-18
- Published: 2025-01-16
- Granted: 2025-07-01
- Earliest claimed: 2022-07-12
- Assignees: Lobe Sciences Ltd.
- Applicants: Lobe Sciences Ltd.
- Inventors: Frederick Sancilio; Yousry Sayed; Maghsoud Dariani; Scott Mough; Shaileshkumar Ramanlal Desai; Autumn Beauchamp
- Web page: https://patentgrep.com/patent/US12344583B2

## CPC

- C07D 209/16: Tryptamines
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Solid forms of psilocin and methods for their production and use with one or more improved properties as compared to psilocin and amorphous psilocin salts thereof are provided.

## Claims

### Claim 1

A solid form of psilocin mucate, at least a portion of which is crystalline and is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 14.71, 15.75, 19.57 and 23.20 2θ, ° using Cu Kα radiation.

### Claim 2 (depends on 1)

The solid form of psilocin mucate of claim 1, wherein the crystalline portion is further characterized by XRPD pattern peaks at about 8.75, 20.93, 23.80 and 30.66 20, ° using Cu Kα radiation.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising the solid form of psilocin mucate of claim 1 and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 1)

An oral pharmaceutical composition comprising the solid form of psilocin mucate of claim 1 and an oral pharmaceutically acceptable carrier.

### Claim 5 (depends on 1)

A method for treating a disease or condition in a subject treatable with psilocin or psilocybin, said method comprising administering to the subject the solid form of psilocin mucate of claim 1.

### Claim 6 (depends on 3)

A method for treating a disease or condition in a subject treatable with psilocin or psilocybin, said method comprising administering to the subject the pharmaceutical composition of claim 3.

### Claim 7 (depends on 4)

A method for treating a disease or condition in a subject treatable with psilocin or psilocybin, said method comprising orally administering to the subject the pharmaceutical composition of claim 4.

### Claim 8

A solid form of psilocin, at least a portion of which is crystalline and is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 14.7147, 15.7522, 19.5746 and 23.203 20, ° using Cu Kα radiation.

### Claim 9 (depends on 8)

The solid form of psilocin of claim 8, wherein the crystalline portion is further characterized by XRPD pattern peaks at 8.7572, 20.931, 23.804 and 30.665 20, ° using Cu Kα radiation.

### Claim 10 (depends on 8)

A pharmaceutical composition comprising the solid form of psilocin of claim 8 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 8)

An oral pharmaceutical composition comprising the solid form of psilocin of claim 8 and an oral pharmaceutically acceptable carrier.

### Claim 12

A solid form of psilocin, at least a portion of which is crystalline and is characterized by an X-ray powder diffraction (XRPD) pattern using Cu Kα radiation depicted in FIG. 1.
